Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population

Annals of Clinical and Laboratory Science

Volumn 36, Issue 2, 2006, Pages 157-162

  Abadie, Jude M ^a,b   Bankson, Daniel D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Electrophoresis; Light chains; Monoclonal gammopathy; Myeloma; Plasma cell dyscrasia

Indexed keywords

IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN;

AGE; ANALYTIC METHOD; ARTICLE; ASSAY; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GENDER; HUMAN; INFORMATION SYSTEM; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SERUM; SERUM FREE LIGHT CHAIN ASSAY; SYMPTOM; TURBIDIMETRY; UNITED STATES; VALIDATION PROCESS; VETERAN;

AGED; BLOOD PROTEIN ELECTROPHORESIS; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; MASS SCREENING; MULTIPLE MYELOMA; NEPHELOMETRY AND TURBIDIMETRY; PARAPROTEINEMIAS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; VETERANS;

EID: 33646501499     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hallek M, Bergsagel P, Andersen P. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
2. Tricot G. New insights into the role of microenvironment in multiple myeloma. Lancet 2000;335:248-250.
3. Kyle R. Multiple myeloma. Review of 869 cases. Mayo Clin Proc 1975;50:29-40.
4. Abraham R, Clark R, Bryant S, Larson T, Kyle R, Katzmann J. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002;48:655-657.
5. Katzmann J, Abraham R, Dispenzier A, Lust J, Kyle R. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005;51:878-881.
6. Lachmann H, Gallimore R, Carr-Smith H, Bradwell A, Pepys M, Hawkins P. Outcomes in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84.
7. Bradwell A: Serum Free Light Chain Analysis, 3rd Ed. The Binding Site Ltd.; Birmingham, UK, 2005, pp 13-21.
8. Rajukumar S, Kyle R, Therneau T, Clark R, Bradwell A, Melton L, et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol 2004;127:308-310.
9. Bakshi N, Guilbranson R, Garstka D, Bradwell A, Keren D. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis (CZE) in detecting subtle FLC M-proteins. Am J Clin Pathol 2005;124:214-218.
10. Katzmann J, Clark R, Abraham R, Bryant S, Lymp J, Bradwell A, Kyle R. Serum and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-1444.
11. Kyle R, Rajkumar S. Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am 1999;13:1181-1202.
12. Drayson M, Tang L, Drew R, Mead G, Carr-Smith H, Bradwell A. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2902.
13. Bradwell A, Carr-Smith H, Mead G, Harvey T, Brayson M. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:489-491.